He Juan, Song Xin
Cancer Biotherapy Center, the Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Zhongguo Fei Ai Za Zhi. 2015 May;18(5):315-20. doi: 10.3779/j.issn.1009-3419.2015.05.10.
Lung cancer, of which approximately 85% are non-small cell lung cancer (NSCLC), is the most leading cause of cancer mortality throughout the world. Despite recent improvements in its treatment, it still remains a highly lethal disease. It is becoming increasingly clear that estrogen and estrogen receptors are involve in the pathogenesis and development of lung cancer. Estrogen receptor modulators and aromatase inhibitor may reverse the drug-resistance of platinum based chemotherapy in NSCLC patients and can enhance curative effect of epidermal growth factor receptor tyrosine kinase inhibitor. In this article the progress in the function of estrogen in NSCLC and the treatment based on the ER signaling pathways for NSCLC is reviewed.
肺癌是全球癌症死亡的首要原因，其中约85%为非小细胞肺癌（NSCLC）。尽管其治疗方法近期有所改进，但它仍然是一种高致死性疾病。越来越明显的是，雌激素和雌激素受体参与了肺癌的发病机制和发展过程。雌激素受体调节剂和芳香化酶抑制剂可能会逆转NSCLC患者铂类化疗的耐药性，并可增强表皮生长因子受体酪氨酸激酶抑制剂的疗效。本文综述了雌激素在NSCLC中的作用以及基于ER信号通路的NSCLC治疗进展。
